​

Zenas BioPharma (ZBIO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ZBIO Stock Forecast

Zenas BioPharma (ZBIO) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $43.33, with a high of $52.00 and a low of $34.00. This represents a 21.03% increase from the last price of $35.80.

$5 $15 $25 $35 $45 $55 High: $52 Avg: $43.33 Low: $34 Last Closed Price: $35.8

ZBIO Stock Rating

Zenas BioPharma stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

ZBIO Price Target Upside V Benchmarks

TypeNameUpside
StockZenas BioPharma21.03%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts333
Avg Price Target$43.33$43.33$43.33
Last Closing Price$35.80$35.80$35.80
Upside/Downside21.03%21.03%21.03%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 2525---7
Oct, 2525---7
Sep, 2525---7
Aug, 2525---7
Jul, 2525---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 28, 2025H.C. Wainwright$44.00$29.6748.30%22.91%
Oct 27, 2025Sean LaamanMorgan Stanley$34.00$31.657.42%-5.03%
Oct 27, 2025Roger SongJefferies$52.00$31.8063.52%45.25%
Oct 08, 2024Roger SongJefferies$35.00$18.7087.17%-2.23%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 28, 2025CitigroupBuyBuyhold
Oct 28, 2025H.C. WainwrightBuyBuyhold
Oct 27, 2025Morgan StanleyOverweightOverweighthold
Oct 27, 2025JefferiesBuyBuyhold
Mar 20, 2025WedbushOutperforminitialise
Feb 04, 2025Wolfe ResearchOutperforminitialise
Oct 08, 2024CitigroupBuyinitialise
Oct 08, 2024JefferiesBuyinitialise
Oct 08, 2024Morgan StanleyOverweightinitialise
Oct 08, 2024GuggenheimBuyinitialise

Financial Forecast

EPS Forecast

$-15 $-12 $-9 $-6 $-3 $0 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-1.18---
Avg Forecast$-8.16$-3.50$-2.99$-3.43
High Forecast$-5.47$-3.15$-1.37$-2.61
Low Forecast$-11.51$-3.71$-3.99$-3.95
Surprise %-85.54%---

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$5.00M---
Avg Forecast$5.00M$5.00M$33.85M$72.73M
High Forecast$12.56M$12.56M$85.00M$182.64M
Low Forecast$635.21K$635.21K$4.30M$9.24M
Surprise %----

Net Income Forecast

$-2B $-2B $-1B $-800M $-400M $0 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-156.13M---
Avg Forecast$-1.12B$-452.72M$-205.30M$-432.93M
High Forecast$-721.98M$-415.77M$-180.83M$-344.49M
Low Forecast$-1.52B$-489.68M$-526.02M$-521.36M
Surprise %-86.07%---

ZBIO Forecast FAQ

Is Zenas BioPharma stock a buy?

Zenas BioPharma stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Zenas BioPharma is a favorable investment for most analysts.

What is Zenas BioPharma's price target?

Zenas BioPharma's price target, set by 5 Wall Street analysts, averages $43.33 over the next 12 months. The price target range spans from $34 at the low end to $52 at the high end, suggesting a potential 21.03% change from the previous closing price of $35.8.

How does Zenas BioPharma stock forecast compare to its benchmarks?

Zenas BioPharma's stock forecast shows a 21.03% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Zenas BioPharma over the past three months?

  • November 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Zenas BioPharma’s EPS forecast?

Zenas BioPharma's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.5, marking a 196.61% increase from the reported $-1.18 in 2024. Estimates for the following years are $-2.99 in 2026, and $-3.43 in 2027.

What is Zenas BioPharma’s revenue forecast?

Zenas BioPharma's average annual revenue forecast for its fiscal year ending in December 2025 is $5M, reflecting a 0% decrease from the reported $5M in 2024. The forecast for 2026 is $33.85M, and $72.73M for 2027.

What is Zenas BioPharma’s net income forecast?

Zenas BioPharma's net income forecast for the fiscal year ending in December 2025 stands at $-453M, representing an 189.97% increase from the reported $-156M in 2024. Projections indicate $-205M in 2026, and $-433M in 2027.